AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20089547 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time counselling by a geriatrician
Number of subjects: 591
Study 20089547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no changes in drug therapy)
Number of subjects: 591
Study 18652103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine IV (10 mg)
Number of subjects: 50
Study 18652103 — intervention group
Group type: COMPARATOR
Intervention: Saline IV (placebo)
Number of subjects: 50
Study 16170406 — intervention group
Group type: EXPERIMENTAL
Intervention: Citol (Abdi Ibrahim Ilaç San. ve Tic A.S., Istanbul, Turkey)
Number of subjects: 26
Study 16170406 — intervention group
Group type: COMPARATOR
Intervention: Cipramil (H. Lundbeck A/S, Copenhagen, Denmark)
Number of subjects: 26
Study 16170406 — intervention group
Group type: COMPARATOR
Intervention: Citol and Cipramil
Number of subjects: 26
Study 12559645 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial interposition (FI) component of a vas occlusion procedure
Number of subjects: 552
Study 12559645 — intervention group
Group type: COMPARATOR
Intervention: No fascial interposition (no-FI) group
Number of subjects: 552
Study 10486792 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous CEE medication (0.625 mg daily) with cyclical supplementation of 5 mg/day of medrogestone acetate for 24 weeks
Number of subjects: 34
Study 10486792 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 34
Study 8942409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium group (n = 7) received selenate-fortified formulas (0.36 mumol Se/L for preterm, 0.22 mumol Se/L for full-term)
Number of subjects: 17
Study 8942409 — intervention group
Group type: COMPARATOR
Intervention: Low-selenium group (n = 10) received non-selenium-fortified formulas (0.12 mumol Se/L for preterm, 0.11 mumol Se/L for full-term)
Number of subjects: 17
Study 8942409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium group
Number of subjects: 17
Study 8942409 — intervention group
Group type: EXPERIMENTAL
Intervention: All infants
Number of subjects: 17
Study 2011986 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (12-week program, 3 times per week)
Number of subjects: 32
Study 2011986 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained normal activities)
Number of subjects: 32
Study 31493626 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH Cristalia
Number of subjects: 135
Study 31493626 — intervention group
Group type: COMPARATOR
Intervention: Genotropin™
Number of subjects: 135
Study 31493626 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH Cristalia and Genotropin™
Number of subjects: 135
Study 30479999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) delivered by respiratory nurses
Number of subjects: 279
Study 30479999 — intervention group
Group type: COMPARATOR
Intervention: Self-help leaflets
Number of subjects: 279
Study 30479999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 279
Study 26965712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation enriched with EPA, arginine, and nucleotides before the operation (group IN)
Number of subjects: 40
Study 26965712 — intervention group
Group type: COMPARATOR
Intervention: No artificial nutrition before the operation (group C)
Number of subjects: 40
Study 22648463 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 60
Study 22648463 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MICT)
Number of subjects: 60
Study 22648463 — intervention group
Group type: COMPARATOR
Intervention: Non-training control group
Number of subjects: 60
Study 20525985 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 2039
Study 20525985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2039
Study 17654236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure (simulated altitude from 4000 to 5500 m) for 3 h per day, 5 days a week, for 4 weeks
Number of subjects: 16
Study 17654236 — intervention group
Group type: COMPARATOR
Intervention: Control normoxic group
Number of subjects: 16
Study 17654236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure
Number of subjects: 16
Study 16147771 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental model of teaching/learning based on a research project
Number of subjects: 173
Study 16147771 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional model of practical activity)
Number of subjects: 173
Study 11792923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg twice daily for 3 weeks
Number of subjects: 86
Study 11792923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 11792923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine and Placebo (regardless of initial treatment)
Number of subjects: 86
Study 10418208 — intervention group
Group type: EXPERIMENTAL
Intervention: Early group (116 patients) - upper arm exercises starting on the third post-operative day
Number of subjects: 344
Study 10418208 — intervention group
Group type: EXPERIMENTAL
Intervention: Later group (115 patients) - upper arm exercises starting on the sixth post-operative day
Number of subjects: 344
Study 10418208 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed group (113 patients) - upper arm exercises after all drains were removed
Number of subjects: 344
Study 10418208 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed group (113 patients)
Number of subjects: 344
Study 7554973 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinylestradiol and gestodene (EE/GSD)
Number of subjects: 46
Study 7554973 — intervention group
Group type: COMPARATOR
Intervention: Monophasic formulation containing 35 micrograms ethinylestradiol and 250 micrograms norgestimate (EE/NGM)
Number of subjects: 46
Study 2345268 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone gel
Number of subjects: 0
Study 2345268 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 2345268 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol gel
Number of subjects: 0
Study 7212503 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative glucose measurements of spot urine specimens
Number of subjects: 246
Study 7212503 — intervention group
Group type: EXPERIMENTAL
Intervention: Home glucose monitoring
Number of subjects: 246
Study 30703780 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted consent
Number of subjects: 200
Study 30703780 — intervention group
Group type: COMPARATOR
Intervention: Verbal consent
Number of subjects: 200
Study 27717999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran EM with bosutinib (100 mg)
Number of subjects: 0
Study 27717999 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran EM alone
Number of subjects: 0
Study 27717999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran EM with bosutinib
Number of subjects: 0
Study 26123638 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO with roller pump
Number of subjects: 22
Study 26123638 — intervention group
Group type: COMPARATOR
Intervention: Matched control
Number of subjects: 22
Study 26123638 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO with centrifugal pump
Number of subjects: 22
Study 25073669 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/day of biphenyl dimethyl dicarboxylate (DDB)
Number of subjects: 135
Study 25073669 — intervention group
Group type: COMPARATOR
Intervention: 300 mg/day of ursodeoxycholic acid (UDCA)
Number of subjects: 135
Study 22186979 — intervention group
Group type: EXPERIMENTAL
Intervention: HZT-501 (ibuprofen 800 mg + double-dose famotidine)
Number of subjects: 0
Study 22186979 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone (800 mg)
Number of subjects: 0
Study 19237607 — intervention group
Group type: EXPERIMENTAL
Intervention: NDRG2-expressing plasmid transfection in SW620 colon cancer cell line
Number of subjects: 99
Study 19237607 — intervention group
Group type: COMPARATOR
Intervention: Mutant NDRG2 (deletion or site-directed mutagenesis)
Number of subjects: 99
Study 16860964 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed numerical information (absolute/relative risk, numbers-needed-to-treat)
Number of subjects: 710
Study 16860964 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Anchoring' to familiar risks or descriptions
Number of subjects: 710
Study 16860964 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical (bar charts, thermometer scales, crowd figure formats)
Number of subjects: 710
Study 16860964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1-3
Number of subjects: 710
Study 16860964 — intervention group
Group type: COMPARATOR
Intervention: Control group information based on British Medical Journal 'Best Treatments'
Number of subjects: 710
Study 12534408 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole (n = 26)
Number of subjects: 50
Study 12534408 — intervention group
Group type: COMPARATOR
Intervention: 40 mg pantoprazole (n = 24)
Number of subjects: 50
Study 10650302 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/progestin replacement therapy
Number of subjects: 2763
Study 10650302 — intervention group
Group type: EXPERIMENTAL
Intervention: High HDL-C (defined by NCEP)
Number of subjects: 2763
Study 10650302 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent correlates of high HDL-C
Number of subjects: 2763
Study 9023640 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg and amoxycillin 1000 mg twice daily for 14 days
Number of subjects: 28
Study 9023640 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg and placebo twice daily for 14 days
Number of subjects: 28
Study 1641608 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-thought-reduction
Number of subjects: 29
Study 1641608 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 29
Study 1641608 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo procedure (imagine high anger‐arousing situations)
Number of subjects: 29
Study 1641608 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 29
Study 6423896 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 2
Study 6423896 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 2
Study 30020252 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity promotion program (WPAPP)
Number of subjects: 26
Study 30020252 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 28069480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 μg)
Number of subjects: 120
Study 28069480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 μg)
Number of subjects: 120
Study 28069480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 μg)
Number of subjects: 120
Study 25566817 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25 or 50 mg for 6 months)
Number of subjects: 300
Study 25566817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 300
Study 25566817 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 300
Study 25566817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24059992 — intervention group
Group type: EXPERIMENTAL
Intervention: TwHF (1‐2 mg·kg⁻¹·d⁻¹)
Number of subjects: 45
Study 24059992 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150‐300 mg/d)
Number of subjects: 45
Study 24059992 — intervention group
Group type: EXPERIMENTAL
Intervention: TwHF combined with irbesartan (TwHF 1‐2 mg·kg⁻¹·d⁻¹ + irbesartan 150‐300 mg/d)
Number of subjects: 45
Study 24059992 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study 21716965 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants following the Columbus Bridge Protocol (4 to 6 implants loaded within 24 hours)
Number of subjects: 49
Study 21716965 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of implants following the ad modum Branemark protocol (6 to 9 implants loaded a mean 8.75 months after surgery)
Number of subjects: 49
Study 19220905 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional media (journals, colleagues, quality circles)
Number of subjects: 449
Study 19220905 — intervention group
Group type: COMPARATOR
Intervention: New media (internet)
Number of subjects: 449
Study 19220905 — intervention group
Group type: EXPERIMENTAL
Intervention: Requirements for media in medical education
Number of subjects: 449
Study 16446006 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype formulation of metoprolol succinate
Number of subjects: 12
Study 16446006 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation Beloc-zok
Number of subjects: 12
Study 15285544 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency excision of sentinel pile
Number of subjects: 0
Study 15285544 — intervention group
Group type: COMPARATOR
Intervention: Conventional excision of sentinel pile
Number of subjects: 0
Study 11447769 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 2 mg tropisetron (single injection)
Number of subjects: 42
Study 11447769 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 2 mg tropisetron (daily for 5 days)
Number of subjects: 42
Study 11447769 — intervention group
Group type: COMPARATOR
Intervention: Peroral daily treatment with 5 mg tropisetron
Number of subjects: 42
Study 9625105 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.7 mg every 2 weeks (group A)
Number of subjects: 304
Study 9625105 — intervention group
Group type: EXPERIMENTAL
Intervention: 29.7 mg every month (group B)
Number of subjects: 304
Study 9625105 — intervention group
Group type: EXPERIMENTAL
Intervention: 148.2 mg every 3 months (group C)
Number of subjects: 304
Study 9625105 — intervention group
Group type: EXPERIMENTAL
Intervention: 382 mg every 6 months (group D)
Number of subjects: 304
Study 9625105 — intervention group
Group type: EXPERIMENTAL
Intervention: 993 mg once (group E)
Number of subjects: 304
Study 7871323 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique applied by operators with previous experience (Group 1)
Number of subjects: 98
Study 7871323 — intervention group
Group type: COMPARATOR
Intervention: Technique applied by operators with no previous experience under supervision (Group 2)
Number of subjects: 98
Study 3045295 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6 mg orally)
Number of subjects: 30
Study 3045295 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg orally)
Number of subjects: 30
Study 3045295 — intervention group
Group type: EXPERIMENTAL
Intervention: Saralasin acetate (50 ng kg‐1 min‐1 intravenous infusion)
Number of subjects: 30
Study 3045295 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 30
Study 3045295 — intervention group
Group type: COMPARATOR
Intervention: Carrier alone
Number of subjects: 30
Study 29236228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 15 mg
Number of subjects: 60
Study 29236228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mg
Number of subjects: 60
Study 29236228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 25 mg
Number of subjects: 60
Study 27762642 — intervention group
Group type: EXPERIMENTAL
Intervention: Black eyelash mascara + Nd:YAG laser (Group I)
Number of subjects: 36
Study 27762642 — intervention group
Group type: EXPERIMENTAL
Intervention: Black eyelash mascara + Alexandrite laser (Group II)
Number of subjects: 36
Study 27762642 — intervention group
Group type: COMPARATOR
Intervention: Control (Nd:YAG laser only for Group I)
Number of subjects: 36
Study 27762642 — intervention group
Group type: COMPARATOR
Intervention: Control (Alexandrite laser only for Group II)
Number of subjects: 36
Study 25654520 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Management (WM) program
Number of subjects: 550
Study 25654520 — intervention group
Group type: EXPERIMENTAL
Intervention: WM+ program (behavior modification)
Number of subjects: 550
Study 25654520 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 550
Study 23719546 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC; 20 mg · kg(‐1) · d(‐1))
Number of subjects: 10
Study 23719546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19481738 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic myomectomy using Laparotenser
Number of subjects: 30
Study 19481738 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic myomectomy (control group)
Number of subjects: 30
Study 18258715 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with paclitaxel plus carboplatin followed by interval debulking surgery and an additional four cycles of postsurgical chemotherapy
Number of subjects: 300
Study 18258715 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS) followed by eight cycles of postsurgical chemotherapy with or without interval debulking surgery
Number of subjects: 300
Study 18258715 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 300
Study 18258715 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS)
Number of subjects: 300
Study 16466688 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing-based cognitive-behavioral therapy (CBT)
Number of subjects: 3
Study 14587411 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material (Iomeprol 300 mgI/ml or 350 mgI/ml) only
Number of subjects: 108
Study 14587411 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material (300 mgI/ml or 350 mgI/ml) flushed with 50 ml of saline solution at a rate of 5 ml/sec
Number of subjects: 108
Study 12141525 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment in infants with RDS
Number of subjects: 21
Study 12141525 — intervention group
Group type: COMPARATOR
Intervention: Control group (preterm infants without RDS)
Number of subjects: 21
Study 9562652 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated protocol: 1.5 M.U. streptokinase infused in 20 min (subgroup A)
Number of subjects: 100
Study 9562652 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol: 1.5 M.U. streptokinase infused in 60 min (subgroup B)
Number of subjects: 100
Study 8461077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline
Number of subjects: 118
Study 8461077 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 118
Study 8461077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 118
Study 3324526 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (mean, 493 +/- 136 mg/day)
Number of subjects: 74
Study 3324526 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (mean, 340 +/- 135 mg/day)
Number of subjects: 74
Study 31726490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight
Number of subjects: 43
Study 31726490 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight
Number of subjects: 43
Study 29273441 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast high-resolution T2WI
Number of subjects: 67
Study 27860499 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin LM75/25
Number of subjects: 54
Study 27860499 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 54
Study 24438516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise during hemodialysis (60 minutes on a cycle ergometer)
Number of subjects: 132
Study 24438516 — intervention group
Group type: COMPARATOR
Intervention: Control (no aerobic exercise)
Number of subjects: 132
Study 24438516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise during hemodialysis
Number of subjects: 132
Study 21742599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroid patients
Number of subjects: 40
Study 21742599 — intervention group
Group type: COMPARATOR
Intervention: Control participants (euthyroid healthy participants)
Number of subjects: 40
Study 19443788 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 110
Study 19443788 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 110
Study 19443788 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent Reinforcement (NR)
Number of subjects: 110
Study 19443788 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Control
Number of subjects: 110
Study 17632765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior history of gallbladder disease
Number of subjects: 2233
Study 17632765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder disease not caused by cholelithiasis
Number of subjects: 2233
Study 17632765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholelithiasis diagnosed within the year before pancreatic cancer
Number of subjects: 2233
Study 17632765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholelithiasis and cholecystectomy within the same time frame
Number of subjects: 2233
Study 17632765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric and/or duodenal ulcers of ≤2 years duration
Number of subjects: 2233
Study 17632765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroidism
Number of subjects: 2233
Study 17632765 — intervention group
Group type: EXPERIMENTAL
Intervention: Other thyroid conditions
Number of subjects: 2233
Study 17632765 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one first-degree relative with pancreatic cancer
Number of subjects: 2233
Study 14724396 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary angioplasty
Number of subjects: 660
Study 14724396 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 660
Study 14724396 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 660